top of page
The Idea

To date, mucosal healing should be the therapeutic goal in inflammatory bowel disease (IBD), as it is associated with sustained clinical remission, reduced rates of hospitalization and operations, as well as a lower incidence of colorectal cancer. We have developed the a multi-immune pathway biomarker test that identifies mucosal healing in IBD patients as early as 3-6 weeks following treatment initiation.

The Technology

To address the various challenges in identifying fast and accurate endoscopic response in clinical practice, as well as the clinical development of novel Ulcerative colitis therapies, Glycominds has developed the UCRI: a unitless multi-immune pathway biomarker test as a surrogate marker for endoscopic response. The UCRI is based on a solid analysis of more than then 10 different innate-immunity and inflammatory biomarkers from different immune pathways.

  • Ensure enrollment of an appropriate Ulcerative Colitis patient population

  • Identify Ulcerative Colitis patients with high disease activity

  • Use a simple blood test as a surrogate marker to detect endoscopic response to treatment in UC

  • Detect endoscopic response within few weeks

  • Use the UCRI for new therapeutic agent dose selection

UCRI - Ulcerative Colitis Response Index Clinical study

Prospective multicenter trial to determine the efficacy and outcome of the UCRI in-vitro diagnostics device to detect treatment response measured by endoscopic healing in moderate to severe Ulcerative Colitis patients treated with Anti-TNF-a.

Scientific Publications
bottom of page